A combination chemoendocrine therapy of mitoxantrone, doxifluridine, and medroxyprogesterone acetate for anthracycline-resistant advanced breast cancer.
Iino Y, Yokoe T, Sugamata N, Maemura M, Takei H, Horiguchi J, Takeyoshi I, Ohwada S, Morishita Y, Kusaba T, Ishida T, Yokomori T, Fujii T, Endo K, Shiozaki H, Aiba S, Takano A, Kishi S.
Iino Y, et al. Among authors: aiba s.
Cancer Chemother Pharmacol. 1998;41(3):243-7. doi: 10.1007/s002800050735.
Cancer Chemother Pharmacol. 1998.
PMID: 9443642
Clinical Trial.